Koshika Soma - Concepedia

Author

Koshika Soma

Pfizer (United States)

Also Known As

Koshika Soma

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)The University of Texas Southwestern Medical Center Metroplex Clinical Research Center University of California, Los Angeles

About

Koshika Soma is an author at Pfizer (United States) specializing in medicine, clinical trials, and rheumatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	1.3K
2	Public Health	1	1	50
3	Social Sciences	1	1	12
4	Epidemiology	1	1	50
5	Immunology	1	1	714

Koshika Soma

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial Gerd R Burmester, Ricardo Blanco, Christina Charles‐Schoeman, The Lancet InflammationRheumatologyRheumatoid DisorderAnti-inflammatoryMedicine	2013	714
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial Roy Fleischmann, Eduardo Mysler, Stephen Hall, The Lancet Rheumatoid DisorderRheumatologyTofacitinib MonotherapyMedicineRheumatic Diseases	2017	479
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study J. Wollenhaupt, Eun-Bong Lee, Jeffrey R. Curtis, Arthritis Research & Therapy	2019	313
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis Kevin Winthrop, Joel C. Silverfield, Arthur Racewicz, Annals of the Rheumatic Diseases	2015	193
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor Christina Charles‐Schoeman, Pierre Wicker, Miguel Á. González‐Gay, Seminars in Arthritis and Rheumatism	2016	132
The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial Kevin Winthrop, Ann Wouters, Ernest Choy, Arthritis & Rheumatology	2017	122
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques Philip G. Conaghan, Mikkel Østergaard, M.A. Bowes, Annals of the Rheumatic Diseases	2016	98
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs Christina Charles‐Schoeman, Gerd R Burmester, Peter Nash, Annals of the Rheumatic Diseases	2015	77
Risk Factors for Major Adverse Cardiovascular Events in Phase <scp>III</scp> and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis Christina Charles‐Schoeman, Ryan DeMasi, Hernán Valdez, Arthritis & Rheumatology	2019	72
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial Vibeke Strand, Eduardo Mysler, Robert J. Moots, RMD Open	2019	51

Page 1